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The appearance of antigen in animals makes 
antigen-specifi  c T cells divide and then die (1, 2). 
It is now well known that the death of these 
cells is to a large extent governed by members 
of the Bcl-2 family of proteins (3–6). Overex-
pression of antiapoptotic members, such as 
Bcl-2 and Bcl-xl (the Protectors), inhibits acti-
vated T cell death (7). Activated T cell death is 
likewise inhibited by double defi  ciencies in the 
Executioner members, Bak and Bax, which are 
supposed to actually kill the T cells (8, 9). 
A third group of proteins in this family, the so-
called Messengers, also aff  ect T cell death, and 
defi  ciencies in one of these proteins (Bim) also 
protect T cells against death (2, 10).
The fact that members of three diff  erent 
groups of Bcl-2−related proteins aff  ect acti-
vated T cell death leads to diffi   culties in pre-
dicting the exact course of events that kills or 
protects the cells. It is agreed that the Protec-
tors somehow prevent death and the Messen-
gers and Executioners drive death. What is not 
clear, however, is which proteins must interact 
with which to control these events. Three 
models have been suggested. In the fi  rst model, 
the Protectors are supposed to be bound to the 
Messengers in healthy T cells and the Execu-
tioners are in some innocuous form. After acti-
vation, as the T cells approach death, it is 
suggested that some of the Messengers are re-
leased from the Protectors and that the freed 
proteins directly or indirectly activate the kill-
ing properties of the Executioners (11–15). In 
a second model, the Protectors are bound to 
the Executioners in healthy cells. When the ac-
tivated T cells approach death, the ratio of 
these proteins changes such that the Execu-
tioners are released from the protective custody 
of the Protectors and, thus freed, are able to kill 
the cell (12, 16). Finally it is possible that the 
Executioners are released to kill the cell via 
some event that does not directly involve bind-
ing to either a Protector or Messenger (17).
The experiments described here test the 
second of these possibilities by examining 
whether the Protectors bind the Executioners 
in healthy cells. We show that the Protector 
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even under conditions in which the Executioners are acti-
vated by incubation in NP-40. Such coprecipitation experi-
ments could not be interpreted with Bcl-xl because we could 
not effi   ciently immunoprecipitate all the protein from normal 
cells. Thus, in a diff  erent approach to the problem, we tested 
the ability of a tagged variant of Bcl-xl lacking its fl  exible loop 
(Bcl-xl∆Loop; references 18–20) to coisolate with Bax or 
Bak after cosynthesis in insect cells. Normal Bcl-xl coprecipi-
tated with both of these proteins; however, Bcl-xl∆Loop did 
not. However, like normal Bcl-xl, Bcl-xl∆Loop bound the 
Messenger protein Bim. In spite of its inability to bind Bak or 
Bax, Bcl-xl∆Loop protected T cells from death as effi   ciently 
as the wild-type protein. Thus, these experiments suggest 
that, in activated T cells, the Protectors act by binding to 
Messengers and not by engaging the Executioners directly.
A byproduct of these experiments is a higher resolution 
structure, by x-ray crystallography, of the structure of Bcl-xl 
bound to a peptide from Bim. This structure diff  ers from 
those that have been previously reported (20–22) in that it 
reveals the confi  guration of a few more of the residues of the 
fl  exible loop (amino acids 22–82) of Bcl-xl. Engagement of 
Bcl-xl by Bim renders a site in the loop sensitive to proteo-
lytic cleavage and changes the conformation of the loop 
amino acids that can be resolved. Moreover, Bcl-xl∆Loop 
binds Bim less well than wild-type Bcl-xl does. Thus, the 
loop domain of Bcl-xl may play a role in some currently un-
known function of Bcl-xl.
RESULTS
Bcl-xl lacking its loop domain protects activated T cells 
from death
The structure of Bcl-xl has been solved by several groups 
(20–22). However, the complete structure of the protein is 
not known. In all reports about Bcl-xl, a portion of the pro-
tein stretching from about amino acids 28–82 could not be 
resolved. To study the contribution of this part of Bcl-xl to 
the protective activity of the protein, we activated T cells 
in vivo with the Vβ8-engaging superantigen, staphylococcal 
enterotoxin B (SEB), isolated the cells 2 d later, and studied 
the ability of transduced wild-type Bcl-xl or Bcl-xl∆Loop 
to protect the activated T cells against death. As shown in 
Fig. 1 A, both constructs of Bcl-xl protected the cells very 
well against death. Unfortunately, because only  5% of the 
T cells were transduced in this and similar experiments, we 
could not evaluate directly how much the Bcl-xl transduc-
tion had increased levels of Bcl-xl in the T cells. Therefore, 
to get some estimate of these values, we compared the levels 
of Bcl-xl in the Phoenix cells that had been transfected either 
with the control plasmid, expressing only Thy1.1 (MIT), 
or with plasmids coding for intact Bcl-xl or Bcl-xl∆Loop. 
Staining showed that between 21 and 25% of the cells were 
transfected with each plasmid. The cells were lysed and Bcl-xl 
was immunoprecipitated with an antibody that reacts with 
both human and mouse Bcl-xl. The immunoprecipitates and 
supernatants were run on SDS-PAGE and Western blotted 
for Bcl-xl. Anti−Bcl-xl precipitated Bcl-xl very ineffi   ciently, 
a consistent fi  nding in our experiments (Fig. 1 B) and one 
that is common to all anti−Bcl-xl antibodies we have used. 
Nevertheless, by combining the data from the immunopre-
cipitates and supernatants we could get an estimate of the in-
crease in Bcl-xl aff  orded by the Bcl-xl−expressing plasmids.
The estimates of Bcl-xl expressed by the transfected genes 
varied somewhat depending on the detergent used, and was 
between 40–100% of endogenous levels in Phoenix. Bcl-xl 
and Bcl-xl∆Loop were expressed equally well (Fig. 1 B).
Bcl-2 does not coprecipitate with Bak or Bax from 
activated T cells
Activated T cells transduced with retroviruses expressing Bcl-2 
are protected from death, like the cells transduced with retro-
viruses expressing Bcl-xl or Bcl-xl∆Loop. To test the idea that 
Bcl-2 protects activated T cells from death by binding to the 
Executioners Bak and Bax, Bcl-2 was precipitated from CHAPS 
or NP-40 lysates of resting and activated T cells, and the pre-
cipitates were analyzed by Western blot for coprecipitation of 
Figure 1.  The loop region of Bcl-xl is not required for its anti-
apoptotic activity in activated T cells. (A) The death of transgenic 
Vβ8+ T cells was followed in vitro after SEB activation in vivo as described 
in Materials and methods. In brief, lymph node T cells were removed from 
Vβ8+ TCR β chain transgenic mice 24 h after SEB injection and trans-
duced with either control MIT retrovirus or MIT expressing either Bcl-xl or 
Bcl-xl∆loop. The viability of Thy1.1+, Vβ8+ T cells bearing either CD4 or 
CD8 was assessed by fl  ow cytometry 24 and 48 h after transduction. In 
this experiment, the rate of T cell death was slowed by incubation of the 
cells overnight in the cold after spinfection and before culture at 37°C. 
Similar results were obtained with cells cultured immediately, in two other 
experiments. Results shown are the means and standard errors of tripli-
cate cultures. (B) Expression of Bcl-xl was compared in Phoenix cells 
transfected with a control plasmid (MIT) coding for Thy1.1 alone or trans-
fected with plasmids coding for Bcl-xl or Bcl-xl∆loop. Phoenix cells were 
lysed in CHAPS (C) or NP-40 (N) and Bcl-xl was immunoprecipitated from 
the lysates with 2H12, anti-human Bcl-xl, or anti-mouse Bcl-xl. 
  Immunoprecipitates were Western blotted as described in materials and 
Methods. Results show the increase in Bcl-xl in Bcl-xl or Bcl-xl∆loop 
transfected cells versus MIT transfected cells.JEM VOL. 203, December 25, 2006  2955
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Bak or Bax. Immunoisolates of Bcl-2 contained neither Bak 
nor Bax (Fig. 2 A). A repeat of this experiment showed that 
the activated T cells were indeed destined to die more rapidly 
than the naive cells (Fig. 2 B) and confi  rmed that Bcl-2 was not 
bound to Bax in either resting or activated T cells but was 
bound, as we have reported before, to Bim in both types of 
cells (reference 23; Fig. 2 C). Similar experiments with 
  immunoprecipitates of Bcl-xl were tried with no consistent 
sign that Bcl-xl was bound to either of the Executioners 
in healthy cells (unpublished data). However, under no cir-
cumstances could we precipitate all the Bcl-xl from the cells. 
As illustrated in Fig. 1 B, only a maximum of 30% of the Bcl-xl 
could be precipitated, even with use of polyclonal antibodies 
under the best of circumstances. Therefore, we could never be 
sure that we had isolated the fraction of Bcl-xl that might be 
associated with Bak or Bax, should such complexes exist. To 
fi  nd out whether or not Bcl-xl bound Bak or Bax in healthy 
T cells, we therefore turned to a diff  erent type of experiment.
Unlike wild-type Bcl-xl, Bcl-xl𝖫L cannot bind a truncated, 
conformationally altered form of Bax
Given our failure to immunoprecipitate Bcl-xl completely 
from T cells and thus examine its intracellular association with 
the Executioners, we decided to test the idea that Bak and 
Bax bind Bcl-xl using insect cells. To perform the test, Bcl-xl 
or Bcl-xl∆Loop were expressed in insect cells, together with 
Bax or 6-His−tagged Bak. The insect cells were lysed with 
NP-40, a detergent, which, like other powerful nonionic de-
tergents, converts innocuous Bax or Bak into their N-
terminal−exposing, death dealing forms that have previously 
been shown to bind Bcl-xl or Bcl-2 (24, 25). Bax was precip-
itated with the anti-BaxNter monoclonal antibody, 6A7, that 
reacts with the supposed death-dealing form of Bax (24).
Figure 2.  In T cells, Bcl-2 is not bound to Bak or Bax. (A) Live rest-
ing and activated T cells were purifi  ed and lysed with CHAPS (C) or NP-40 
(N) as described in Materials and methods. Lysates were tumbled over-
night with beads coupled to anti−Bcl-2 and washed and eluted as 
described in Materials and methods. Material bound to the beads or 
supernatants from the beads were run with the indicated cell equivalents 
and blotted as shown. Results are representative of at least three inde-
pendent experiments. (B) In a separate experiment the rates of death of 
resting or activated T cells were measured in culture. Results shown are 
the means and standard errors of triplicate cultures. (C) The remainder of 
these cells were lysed in CHAPS (C) or NP-40 (N), lysates were immuno-
precipitated with anti-Bcl-2, and the immunoprecipitates and superna-
tants were Western blotted for Bcl-2, Bax, and Bim.
Figure 3.  The loop region of Bcl-xl is essential for interaction with 
Bax and Bak. The interactions of Bax with Bcl-xl and Bcl-xl∆loop were 
studied in baculovirus-infected High Five insect cells as described in 
  Materials and methods. In brief, insect cells were coinfected with baculovirus 
expressing Bax and a second virus expressing either Bcl-xl or Bcl-xl∆loop. 
(A) After 4 d, whole cell lysates (105) or anti-Bax (mAb 6A7) precipitates 
from the lysates of 5 × 105 infected cells were analyzed by SDS-PAGE 
and blotted with anti−Bcl-xl antibody. (B) Same as A except baculovirus-
expressing 6-His−tagged Bak instead of Bax was used and the precipita-
tion was performed with the Ni-NTA beads. (C) Phoenix cells were 
cotransfected with Bax and a full-length version of either Bcl-xl or 
Bcl-xl∆loop as described in Materials and methods. Total cell lysates and 
anti-Bax immunoprecipitates were analyzed by SDS-PAGE and blotting 
with anti-Bax as in A. Care was taken throughout to ensure equal cell 
equivalents were loaded in each lane.2956  BCL-XL PROTECTS WITHOUT BINDING TO BAK AND BAX | Liu et al.
Immunoisolation of Bax from the NP-40 lysates readily 
coprecipitated Bcl-xl. Bcl-xl∆Loop, however, did not coiso-
late with Bax. Likewise, Bak coprecipitated with wild-type 
Bcl-xl but not with Bcl-xl∆Loop (Fig. 3). To check that this 
was not some artifact caused by the environment inside insect 
cells, we repeated the experiment with transfections in Phoe-
nix cells (Fig. 3 C). Again, Bax coisolated with Bcl-xl but not 
with Bcl-xl∆Loop. As expected, Bax did not coprecipitate 
with Bcl-xl if the Phoenix cells were lysed in CHAPS rather 
than NP-40 (unpublished data). This result was refl  ected in 
the degree of conformational change of Bax by NP-40, with 
virtually none of the cellular Bax reacting with the anti-con-
formationally changed Bax antibody 6A7 after Phoenix of T 
cell lysis in CHAPS and up to 70% of the Bax reacting with 
6A7 after lysis in NP-40 (Fig. 4).
To demonstrate that the Bcl-xl∆Loop was functional 
in insect cells, we coexpressed, in the cells, Bcl-xl or Bcl-
xl∆Loop together with Bim, a protein to which Bcl-xl binds 
well. Both forms of Bcl-xl were associated with Bim, al-
though less Bcl-xl∆Loop bound to Bim than Bcl-xl did, 
especially in the case of BimEL (Fig. 5).
Thus, Bcl-xl∆Loop does not bind Bak or Bax, even when 
the latter proteins are conformationally changed to their sup-
posed death-dealing form. Nevertheless, Bcl-xl∆Loop pro-
tects activated T cells from death, suggesting that interaction 
of Bcl-xl with conformationally altered Executioners is not 
important to the protective eff  ects of Bcl-xl.
The fl  exible loop of Bcl-xl is affected by binding 
of Bcl-xl to Bim
These experiments led us to be curious about the functions of 
Bcl-xl’s fl  exible loop. Somehow this loop aff  ects the ability of 
Bcl-xl to bind the conformationally changed forms of the 
Executioners, even though this interaction is not important 
in the ability of Bcl-xl to protect T cells from death. Also, the 
loop modestly aff  ects the ability of Bcl-xl to bind intact Bim, 
even though the major site of this interaction is thought to be 
via the engagement of Bim’s Bcl-2 homology 3 (BH3) region 
by the BH3 binding groove of Bcl-xl, a site on Bcl-xl that 
does not include Bcl-xl’s fl  exible loop.
To address the function of Bcl-xl’s loop, we made an-
other attempt to resolve its structure. To this end, hanging 
drops containing Bcl-xl and Bim were set up, with each pro-
tein lacking only its transmembrane region. Crystals appeared. 
Their characteristics, shown in Table I, revealed some diff  er-
ences between these crystals and those we have previously 
reported between Bcl-xl and a fragment of Bim (22). Most 
notably, the new crystals diff  racted to a 1.2-Å resolution, al-
lowing a much higher quality electron density map and anal-
ysis of the complex (Fig. 6 A).
As before, the crystals contained Bcl-xl bound to a pep-
tide of Bim. The Bim protein had, once again, been degraded 
by proteolysis during the time the crystals took to form (Fig. 
6 B). In general, the conformation of Bcl-xl in this new com-
plex was very similar to that previously reported (20-22) with 
the exception that the Bim peptide was somewhat shorter at 
both ends than that which we observed in our previous struc-
ture (Fig. 6 C). This allowed for a change in the crystal pack-
ing, accounting for the changes in crystal parameters between 
this and our previous paper (22). Nevertheless, the Bim pep-
tide was bound to Bcl-xl very much as before with hydro-
phobic and hydrophilic interactions allowing a very stable 
complex and similar changes in the structure of Bcl-xl by 
comparison with its unengaged fold.
Figure 4.  Lysis in NP-40 changes the conformation of Bax. Phoe-
nix cells were transfected with a control plasmid (MIT) expressing Thy1.1. 
These cells, and resting or activated T cells, were lysed in CHAPS or NP-40. 
The lysates were immunoprecipitated with the anti−N-terminal Bax anti-
body 6A7. Bax immunoprecipitated by 6A7 is here termed DeN. Immuno-
precipitates and their supernatants were Western blotted for Bax. Shown 
are the results of immunoprecipitates of 12.5 × 106 Phoenix cells or 107 
resting or activated T cells and the supernatants of 106 of each of these 
cells. Also indicated are the ratios of Bax obtained in the immunoprecipi-
tates versus all Bax in the cells.
Figure 5.  Role of the loop region of Bcl-xl in interactions with 
Bim. The interactions of various versions of Bim with Bcl-xl and Bcl-
xl∆loop were studied in baculovirus-infected High Five insect cells 
as described in Materials and methods. In brief, insect cells were 
  coinfected with baculovirus expressing one of the versions of 6-His−
tagged Bim (BimEL, BimL, BimEL∆TM, and BimL∆TM) and a second virus 
  expressing either Bcl-xl or Bcl-xl∆loop. After 4 d, Ni-NTA precipitates 
from lysates of equal numbers of the infected cells (5 × 105) were 
  analyzed by SDS-PAGE and blotted with anti−Bcl-xl antibody. Care was 
taken throughout to ensure that equal cell equivalents were loaded in 
each lane.JEM VOL. 203, December 25, 2006  2957
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Most of the loop region between Bcl-xl’s α1 and α2 he-
lices remained unresolved in this new structure. The higher 
resolution of these crystals allowed us to see some of the 
amino acids at the beginning and end of the loop that had not 
previously been visible in complexes between Bcl-xl and 
BH3 peptides, but that were, to some extent, seen in the 
structure of Bcl-xl alone (20–22). Thus our new structure 
showed that the conformation of the N-terminal end of the 
Bcl-xl loop domain is changed by binding to Bim (Fig. 7, A 
and B). In free Bcl-xl, a hydrophobic pocket formed between 
Bcl-xl’s α1 and α5 helices is occupied by Phe27, whereas in 
the Bcl-xl−Bim BH3 complex, the pocket is occupied by 
Trp24. Likewise, in free Bcl-xl the stretch of amino acids 
22–28 has an extended helix-like conformation, whereas this 
region is completely linearized in the Bcl-xl−Bim BH3 
complex. At the other end of the loop, clear density and low 
temperature factors can be seen for amino acids 79–82 and, in 
the complex, these amino acids are interacting stably with the 
body of Bcl-xl (Fig. 7 C). The easy identifi  cation of these 
amino acids in the complex, but not in free Bcl-xl, suggests 
that they have changed position in the complexed versus free 
Bcl-xl and are now attached more intimately to the rest of 
the protein.
Engagement of Bim makes Bcl-xl’s loop susceptible 
to proteolysis
Even at the high resolution of our new crystal, electron den-
sity for the loop faded gradually after Phe27, indicating that 
the rest of the loop is relatively unstructured. At the C-terminal 
end of the loop, however, electron density reappeared 
abruptly at Glu79, suggesting that in the crystal Bcl-xl may 
have been cleaved at this point (Fig. 7). To test this, we ran 
the protein in the crystal on SDS-PAGE and found fragments 
that were consistent with proteolysis of Bcl-xl (Fig. 8). Such 
fragments were not seen in the preparation of Bcl-xl before it 
was set up to crystallize, nor in crystallization drops set up at 
the same time as those analyzed in Fig. 8, but containing Bcl-xl 
without Bim. Because all the proteins were purifi  ed similarly 
Figure 6.  The overall structure of Bcl-xl−Bim. (A) The 2Fo-Fc elec-
tronic density (1.4σ cutoff) of the BH3 region of the Bim peptide. Three 
conserved BH3 hydrophobic amino acids, L94, I97, and F101, are labeled. 
(B) A ribbon representation of the complex of Bcl-xl and the Bim 
fragment. The eight α helices of Bcl-xl are labeled and colored sequentially: 
yellow, orange, red, blue, green, cyan, magenta, and purple. (C) A superim-
position (Swiss PDB Viewer [reference 47]) of the current and previous 
(available from GenBank/EMBL/DDBJ under accession no. 1PQ1) 
Bcl-xl−Bim complexes.
Table I. Data collection and refi  nement statistics
Data collection
Data set Bcl-xL−Bim
Space group P21
Unit cell dimensions (Å) a = 36.52
b = 46.21
c = 51.18
Unit cell angles (°) β = 100.25
Number of molecules in AU 1
Resolution limits (Å) 20.0−1.20 (1.28−1.20)a
Unique refl  ections 49,728 (6,983)
Completeness (%) 92.1 (77.4)
Average redundancy 3.1 (2.7)
Average I/σ 9.2 (2.2)
Rmerge(%)b 7.4  (47.8)
Refi  nement
Data set Bcl-xL−Bim
Resolution (Å) 20.0−1.20
I/σ cut off  1.0
Total refl  ections 48,364 (6,410)
Refl  ections used for Rfree 2,460 (317)
Rworking (%)c 20.8 (25.3)
Rfree (%) 21.2 (27.6)
Average B factors (Å2) 16.0
Ramachandran data (% of residuesd in:)
 Favored  regions
 Allowed  regions
  Generously allowed regions
 Disallowed  regions
95.9
4.1
0.0
0.0
Rmsd
Bonds (Å)
 Angles  (°)
  B factor main chain (Å2)
  B factor side chain (Å2)
  Cross-validated coordinate error (Å)
0.004
1.01
0.89
1.40
0.4
aAll data (outer shell).
bRmerge = ∑ (|I − <I>|)/∑ (I).
cRworking/free = ∑||Fo| − |Fc||/∑|Fo|.
dExcluding glycine and proline.2958  BCL-XL PROTECTS WITHOUT BINDING TO BAK AND BAX | Liu et al.
from insect cell supernatants, and thus had the same chance of 
contamination with insect cell proteases, we concluded that 
engagement of Bcl-xl by Bim may have rendered the fl  exible 
loop of Bcl-xl susceptible to proteolysis.
DISCUSSION
In spite of many years’ work, we still don’t know exactly 
how the Executioners Bak and Bax are triggered to kill acti-
vated cells. The work described here suggests that in T cells 
triggering does not occur because of release of Bak and Bax 
from the embrace of Protectors such as Bcl-2 and Bcl-xl. We 
can see no evidence that Bcl-2 binds the innocuous forms of 
Bak or Bax in T cells. Bcl-xl in both its intact and truncated 
(Bcl-xl∆Loop) form protects T cells from death. Neverthe-
less, Bcl-xl∆Loop does not bind the Executioners, even after 
they have been converted by incubation in NP-40 to their 
cell-killing forms (24). One could argue that this latter ex-
periment was done only in insect or Phoenix cells and not in 
the environment of interest, i.e., in activated T cells, where 
conditions may be diff  erent. Although this is possible, we 
think it unlikely, especially because in the insect cells, for ex-
ample, both Bcl-xl and Bcl-xl∆Loop are well able to bind a 
verifi  ed partner (Bim) for these proteins.
It could be that Bcl-xl∆Loop does not function in the 
same way as normal Bcl-xl. For example, both proteins may 
bind Bim, as shown here, but denatured Bax and Bak may be 
able to displace Bim from Bcl-xl but not from Bcl-xl∆Loop. 
If this were correct, one might expect Bcl-xl∆Loop to be a 
better Protector than Bcl-xl. However, that doesn’t seem to 
be the case. Activated T cells appear to be equally well pro-
tected by the two proteins (Fig. 1), suggesting that the two 
proteins act similarly.
The involvement of Bcl-xl’s fl  exible loop in the binding 
of the protein to Bax after cell solubilization in NP-40 has 
been studied previously (19) in the paper that fi  rst investi-
gated the functions of the loop. Chang et al. (19) reported 
that Bcl-xl lacking its loop continued to bind Bax, a result 
that is exactly the opposite to that reported here. There are 
several diff  erences in methodology and cell type that could 
account for the discrepancy. One explanation stems from the 
fact that in the previous paper, the band that coprecipitated 
with Bcl-xl∆Loop was identifi  ed as Bax on the basis of its 
molecular weight, not by Western blot with a specifi  c anti-
body. Bax and Bim have approximately the same molecular 
weight, and the band thought to have been Bax could have 
been some other protein of similar molecular weight, e.g., 
Bim, a protein which is known to bind Bcl-xl (15, 23).
The function of Bcl-xl’s fl  exible loop, and the compara-
ble structure on Bcl-2, has long been a mystery. Several pa-
pers have shown that the ability of these proteins to protect 
cells from death is more or less unaff  ected by absence of their 
loops (18, 26, 27), which is a result we confi  rm here. Indeed, 
sometimes the absence of the loop improves the antiapop-
totic activities of the proteins (19, 28). This may be because 
serines on the loops can be phosphorylated, and such 
Figure 7.  Details of the Bcl-xl loop region. The beginning of the 
loop region of free Bcl-xl (available from GenBank/EMBL/DDBJ under 
accession no. 1PQ1; A) and the Bcl-xl−Bim complex (B) are shown as 
ribbon representations colored as in Fig. 1. Wire frame representations of 
Tyr22, Trp24, and Phe27 are also shown, with CPK coloring. This fi  gure 
was created with WebLab Viewer Pro. (C) Wire frame representations of 
the amino acids of Bcl-xl, which contact the end of the loop domain 
(amino acids 79−82) are shown (CPK coloring). The contact surface of 
amino acids 79−82 with the rest of the molecule is also shown shaded 
from light gray (closer) to dark gray (distant). This fi  gure was created with 
Protein Explorer (reference 48).
Figure 8.  Cleavage of the Bcl-xl loop region during crystallization. 
The contents of hanging drops containing crystals of either Bcl-xl alone 
(left) or Bcl-xl and Bim (right) were subjected to SDS gel analysis. The 
samples were prepared from crystallization trays after 11 mo of incuba-
tion at 4°C.JEM VOL. 203, December 25, 2006  2959
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phosphorylation inhibits the protective and increases the 
death-dealing properties of the proteins (28–30).
It has also been reported that asparagines in the fl  exible 
loop of Bcl-xl can be deamidated in tumor cells in response 
to DNA damage (31, 32) and that deamidation renders Bcl-xl 
less able to block the proapoptotic activity of BH3-only mes-
senger proteins. This result suggests a relationship between 
Bcl-xl’s engagement of a Messenger protein such as Bim and 
the structure of Bcl-xl’s loop. As such, the result is reminis-
cent of our fi  nding that although Bim engages Bcl-xl very 
well via binding of its BH3 region to the BH3 binding groove 
of Bcl-xl, somehow engagement of Bim’s BH3 aff  ects the 
structure of Bcl-xl’s fl  exible loop.
Finally, caspase-dependent cleavage of the fl  exible loop 
of Bcl-xl, a phenomenon that converts Bcl-xl into a pro-
apoptotic protein (33, 34), has been described. Interestingly, 
one of the cleavage sites reported is only two amino acids 
away from Glu79, the amino acid at the N terminus of one 
of the Bcl-xl fragments we found in our crystal structures. 
Perhaps the protein is particularly sensitive to proteolysis in 
this region, particularly after engagement of Bim.
In summary, the data presented here suggest that the Ex-
ecutioners are not kept in check by binding to antiapoptotic 
proteins. How then are the Executioners triggered? Most 
likely, in activated T cells, this process begins when, as anti-
gen disappears from animal, levels of Bcl-2 in the activated T 
cells fall without a concomitant fall in levels of Bim (35). In 
healthy T cells, most of the Bim in the cell is bound to Bcl-2 
or Bcl-xl (23). We predict that when Bcl-2 levels fall in T 
cells, some Bim is released. The free Bim then directly or in-
directly causes Executioner activation.
At fi  rst thought, this hypothesis is opposed by our fi  nding 
that Bcl-xl∆Loop protects activated T cells as effi   ciently as 
wild-type Bcl-xl does, and yet the former protein binds Bim 
less well than the latter. These apparently contradictory re-
sults may be reconciled by the observation that Bcl-xl∆Loop 
binds BimL quite well and, in fact, binds BimL lacking a 
transmembrane region as effi   ciently as Bcl-xl does (Fig. 5). 
BimL may be a more eff  ective mediator of T cell death than 
BimEL because the latter can be ubiquitinylated and degraded 
after phosphorylation of a serine residue that is absent in 
BimL (36, 37). It is also possible that Bim’s transmembrane 
region is not available to interfere with the binding of Bcl-
xl∆Loop when T cells are being protected from death.
We do not know how the freed Bim acts to mediate cell 
death because, in the same way that we cannot see association 
between Protectors and Executioners, we cannot measure any 
association between Bim and Bak or Bax. Perhaps Bim acts, 
as has been suggested in the past, via “hit and run” in which a 
very quick, low level interaction between Bim and the Exe-
cutioners catalyzes a catastrophic change in the conformation 
of a large amount of the Executioner proteins (13).
MATERIALS AND METHODS
Measurement of the antiapoptotic activity of Bcl-xl and Bcl-xl𝖫Loop. 
Constructs of Bcl-xl and Bcl-xl∆Loop (Bcl-xl lacking amino acids 
45–84; reference 21) were cloned into a plasmid version of the Thy1.1 
expressing retroviral construct MIT (38) and cotransfected by standard 
methods with pCL-Eco (a plasmid vector expressing the structural proteins 
of Maloney murine leukemia virus; a gift of I. Verma (Salk Institute, La Jolla, 
CA [reference 39]) into the packaging cell line Phoenix-Eco. Activated T 
cells were purifi  ed from the lymph nodes of mice expressing a Vβ8+ trans-
gene, VβDO (23), which had been treated 2–3 d before with 100 μg of 
mouse SEB, which is a Vβ8-specifi  c superantigen that activates all the T cells 
in VβDO mice. The activated T cells were transduced with retrovirus by 
centrifugation at 1000 g for 2 h, followed by washing and incubation at 37°C 
in Dulbecco’s enriched culture medium. In some experiments, death of the 
cells was slowed by maintaining them in the cold overnight after the spinfec-
tion and before culture at 37°C. At various times thereafter, the cells were 
stained with antibodies against Vβ8, Thy-1.1, and either CD4 or CD8 and 
analyzed on a FACSCalibur fl  ow cytometer (Becton Dickinson). The viabil-
ity of Thy-1.1+/Vβ8+ cells bearing either CD4 or CD8 was determined by 
FSC/SSC gating (38, 40).
Use of mice for these experiments has been approved by the National 
Jewish Medical and Research Center Animal Care and Use Committee.
Analysis, by immunoprecipitation, of association between Bcl-2 
and Bak or Bax in T cells. T cells were purifi  ed from VβDO mice, which 
were untreated or had been treated 2 d before with 100 μg SEB to yield 
resting and activated cells, respectively. The cells were lysed with solutions 
containing protease inhibitors and 2% CHAPS or 0.5% NP-40 and spun at 
14,000 rpm in a microfuge for 15 min to remove nuclei and unlysed cells. 
The lysates were incubated overnight with beads coupled to hamster 
anti−Bcl-2, 3F11 (41). The beads were then extensively washed. Bound 
proteins were released by boiling in SDS loading buff  er, run on 10–20% gra-
dient gels (Bio-Rad Laboratories), and Western blotted with mouse 
anti−human and mouse Bcl-2 (Zymed Corp.), rabbit anti-Bak NT (Upstate 
Biotechnology), or rabbit anti-Bax N-20 (Santa Cruz Biotechnology, Inc.). 
Secondary antibodies were horseradish peroxidase−coupled donkey 
anti−mouse IgG or donkey anti−rabbit IgG (The Jackson Laboratory). In 
experiments in which we failed to satisfactorily immunoprecipitate, Bcl-xl 
lysates were tumbled overnight with excess beads bearing two diff  erent ham-
ster anti−Bcl-xl antibodies: 2H12 (24) or Ham151-297.5 (unpublished data) 
or rabbit polyclonal anti−Bcl-xl (Transduction Laboratories). Bcl-xl was 
Western blotted with rabbit anti−Bcl-xl (Transduction Laboratories) fol-
lowed by donkey anti−rabbit IgG (The Jackson Laboratory).
Analysis by immunoprecipitation of the association of Bcl-xL or 
Bcl-xL𝖫loop with Bak or Bax. Baculoviruses encoding Bak, Bax, 6-
His−tagged Bcl-xl lacking its transmembrane region (Bcl-xl∆Mem), or lac-
king both its transmembrane region and its fl  exible loop (amino acids 45–84 
[Bcl-xl∆Loop∆Mem]) were constructed as previously described (22, 42). 
High Five insect cells (Invitrogen) were coinfected with viruses expressing 
either Bak or Bax and with viruses expressing one of the forms of Bcl-xl. 
4 d later the cells were lysed in Ni-NTA binding buff  er by sonication. 0.5% 
NP-40 was added to the lysis buff  er to increase the likelihood that Bcl-xl 
would bind Bak or Bax (24). After centrifugation (13,000 g for 60 min), su-
pernatants were incubated with beads bearing an antibody to activated Bax 
(6A7 [reference 23]) or Ni-NTA beads for 1 h in 4°C. After thorough wash-
ing using the binding buff  er, complexes were isolated by boiling in SDS 
loading buff  er, run on SDS-PAGE, and Western blotted as described in the 
previous paragraph.
To study the interaction of Bcl-xl and Bax in Phoenix cells, Bax was 
cloned into the MIT plasmid (38). Phoenix cells were cotransfected with the 
Bax plasmid and the MIT plasmid encoding either Bcl-xl or Bcl-xl∆Loop as 
described in Measurement of the antiapoptotic activity..., except that the 
pCL-Eco helper plasmid was omitted. Transfected cells were incubated at 
37°C. After 24 h, their supernatants were replaced with new Dulbecco’s en-
riched culture medium. After another 24 h, cells were harvested and the cell 
pellets were lysed with 0.5% NP-40 in PBS buff  er (50 mM NaH2PO4-
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centrifugation at 10,000 g for 30 min. Bax was immunoprecipitated from the 
lysate with the 6A7 monoclonal antibody (24) and subjected to SDS-PAGE. 
Any Bcl-xl associated with the immunoprecipitated Bax was detected by 
blotting the gel with anti-Bcl-xl antibody.
Coprecipitation of Bim with Bcl-xL or Bcl-xL𝖫loop. Baculoviruses 
encoding BimEL−6-His, BimL−6-His, BimEL∆Mem−6-His, and 
BimL∆Mem−6-His were constructed and used to coinfect insect cells with 
viruses expressing Bcl-xl∆Loop or Bcl-xl∆Loop∆Mem. 4d later, complexes 
were isolated from the insect cells. Equal cell equivalents of every sample were 
loaded, separated by SDS-PAGE, transferred to nitrocellulose membranes, and 
blotted with an anti−Bcl-xl antibody (Santa Cruz Biotechnology, Inc.).
Preparation of the complex of Bcl-xl and Bim. The cDNA fragment 
encoding amino acids 1–196 of mouse Bcl-xl was cloned under the control 
of the polyhedron promoter into a previously described baculovirus transfer 
plasmid (22, 42). Active virus was made by cotransfection into SF9 insect 
cells (Invitrogen) of the plasmid and BacVector 3000 baculovirus DNA 
(Novagen) by the calcium phosphate coprecipitation method. A high tittered 
virus stock was made by further propagation in SF9 cells. Virus producing 
BimL with an additional C-terminal 6-His tag was made by the same method 
(22). The C-terminal membrane interaction domain of BimL was truncated 
to increase the solubility of the protein (BimL∆Mem).
To prepare the complex of Bcl-xl and Bim, High Five insect cells were 
coinfected with the two viruses and cultured for 24 h at 27°C. The infected 
cells were then moved to 19°C and harvested by centrifugation (1,500 g for 
10 min) 4 d later. The cells were lysed by sonication in Ni-NTA binding 
buff  er (50 mM Na2HPO4, 300 mM NaCl, and 5 mM imidazole, pH 8.0). 
Lysates were cleared by high-speed centrifugation (100,000 g for 60 min), 
and proteins were purifi  ed from the supernatant using Ni-NTA columns 
(QIAGEN). The Bcl-xl−Bim complex was eluted from the column with 
500 mM imidazole and purifi  ed by Superdex 200 size exclusion column (GE 
Healthcare) in PBSA buff  er (50 mM NaH2PO4-Na2HPO4, 150 mM NaCl, 
and 5 mM NaN3, pH 7.5). The complex was further purifi  ed using ion ex-
change chromatography on a Mono-Q column (GE Healthcare) and a Tris-
NaCl gradient (25 mM Tris, 100–1,000 mM NaCl, pH 8.2). The complex 
was concentrated to 15 mg/ml in Tris-NaCl buff   er (10 mM Tris and 
100 mM NaCl, pH 8.2) for crystallization.
Crystallization and data collection. Crystallization trays were set up us-
ing the hanging drop vapor diff  usion method. Equal amounts of protein so-
lution and mother liquor (25% PEG4000, 0.1 M NaAc, pH 4.6, and 0.2 M 
(NH4)2SO4) were mixed in the hanging drops. After  11 mo at 4°C, crystals 
appeared. The crystals were fl  ash-frozen in liquid nitrogen after brief transfer 
to a solution containing the mother liquor supplemented with 20% glycerol. 
A 1.2-Å high-resolution diff  raction dataset was collected under cryogenic 
conditions at beam line SBC 19BM at Advanced Photon Source at Argonne 
National Laboratory. The data were processed with HKL2000 package (43). 
The data processing results are summarized in Table I.
Structure determination and refi  nement. The structure of the Bcl-xl−Bim 
complex was determined by molecular replacement. The mouse Bcl-xl 
crystal structure (available from GenBank/EMBL/DDBJ under accession 
no. 1PQ0) was used to determine the initial phases of Bcl-xl−Bim. AMoRe 
(44, 45) was used to fi  nd the initial position of the molecules. The CNS suite 
(46) was used for further refi  nement. At the beginning of refi  nement, the α2 
and α3 helices around the BH3 binding groove of Bcl-xl were omitted 
because of large discrepancies in the initial electronic density map. After a 
few cycles of refi  nement, α2 and α3 were rebuilt based on 2Fo-Fc and Fo-
Fc electronic density maps. The Bim peptide in the binding groove was built 
later, taking advantage of a previous structure of Bcl-xl bound to a Bim 
peptide (available from GenBank/EMBL/DDBJ under accession no. 1PQ1). 
Finally, we built as much of the details of the Bcl-xl loop region as we could, 
ending at Phe27 and beginning again at Glu79. There was still some 
continuous electronic density after Phe27, but this was not strong enough 
to allow us to build in additional residues. In contrast, the electronic density 
diminished abruptly preceding Glu79. Hydrogen atoms were built in and 
refi  ned in the last cycles. The structure was refi  ned to 1.2 Å and 252 water 
molecules were added to the fi  nal structure. The results of the refi  nement are 
summarized in Table I. All fi  gures were constructed with WebLab Viewer 
Pro (Accelrys Inc.).
Atomic coordinates of the Bcl-xL−Bim complex reported here have 
been deposited in the Protein Data Bank (accession no. 1TD8).
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